Mirati Therapeutics, Inc MRTX Stock Price, Quote & News

In the past three faq moratoriums, Mirati Therapeutics insiders have not sold or bought any company stock. Provide specific products and services to you, such as portfolio management or data aggregation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

• CompareMRTX’s historical performanceagainst its industry peers and the overall market.
• MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
• © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
• Only 3 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days.
• High-growth stocks tend to represent the technology, healthcare, and communications sectors.

The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road… According to 14 analysts, the average rating for MRTX stock is “Buy.” The 12-month stock price forecast is $80.29, which is an increase of 74.77% from the latest price. Investing.com – Mirati Ther reported on Tuesday third quarter erl-41315||earnings that beat analysts’ forecasts and revenue that topped expectations.

MRTX Related stocks

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Only 3 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. Only 7 people have searched for MRTX on MarketBeat in the last 30 days. MarketBeat has tracked 2 news articles for Mirati Therapeutics this week, compared to 2 articles on an average week.

Mirati Therapeutics does not have a long track record of dividend growth.

MRTX Stock – Frequently Asked Questions

Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.

Real-time quotes, advanced visualizations, backtesting, and much more. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Real-time analyst ratings, insider transactions, earnings data, and more.

Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage

Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade. MRTX, -0.81% were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administrati… MRTX, +0.10% jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Kraza… This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and accommodation requests. Bloomberg Markets The Close Romaine Bostick breaks down the day’s top stories and trading action leading into the close. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. IND demonstrates Mirati’s leadership in KRAS, representing the Company’s third KRAS or KRAS-signaling program to enter clinical development SAN DIEGO , Jan. 19, 2023 /PRNewswire/ — Mirati Therapeutic… By creating a free account, you agree to our terms of service.

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors. Realtime quote and/or trades are not sourced from all markets.

Mirati Therapeutics reports a narrower-than-expected Q4 loss and records first sales of Krazati. Mirati Therapeutics’ stock is owned by many different retail and institutional investors. Top institutional shareholders include Fiera Capital Corp (1.22%), National Bank of Canada FI (0.59%), Assenagon Asset Management S.A. (0.44%), Allspring Global Investments Holdings LLC (0.40%), State of New Jersey Common Pension Fund D (0.09%) and Simplex Trading LLC (0.00%). The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.

According to analysts’ consensus price target of $80.87, Mirati Therapeutics has a forecasted upside of 74.1% from its current price of $46.44. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

News flow

The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more. Barchart is committed to ensuring digital accessibility for individuals with disabilities.

There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares. Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The firm’s products target the genetic and immunological promoters of cancer.

Analyst Ratings

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month.

• We’d like to share more about how we work and what drives our day-to-day business.
• Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
• You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MRTX quote.
• The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.

By Investing.com Staff Stocks closed solidly higher Tuesday as strong earnings from retailers, including Best Buy, allayed concerns that the consumer is weak into the holiday season. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.

https://1investing.in/, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price.

The P/E ratio of Mirati Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Mirati Therapeutics has received a 74.62% net impact score from Upright. Mirati Therapeutics has a short interest ratio (“days to cover”) of 8.6. Mirati Therapeutics has only been the subject of 1 research reports in the past 90 days.

Recently Viewed Tickers

Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Investing.com – U.S. equities were higher at the close on Monday, as gains in the Oil & Gas, Basic Materials and Industrials sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Friday, as gains in the Telecoms, Financials and Industrials sectors propelled shares higher. Join thousands of traders who make more informed decisions with our premium features.

15.80% of the outstanding shares of Mirati Therapeutics have been sold short. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.

Mirati Therapeutics share price live 45.81, this page displays NASDAQ MRTX stock exchange data. View the MRTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mirati Therapeutics real time stock price chart below.